S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

BACKGROUND: There are currently limited systemic treatment options for patients with advanced neuroendocrine tumours (NETS) and the efficacy of existing treatments is sub-optimal. We evaluated the efficacy and safety of Tegafur/gimeracil/oteracil/potassium capsules (S-1)/Temozolomide with or without...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Yihebali, Song, Lijie, Liu, Weili, Zhou, Yuhong, Miao, Yadong, Fang, Weijia, Tan, Huangying, Shi, Susheng, Jiang, Hai, Xu, Jianming, Jia, Ru, Zheng, Bo, Jiang, Liming, Zhao, Jiuda, Zhang, Rui, Tan, Huijing, Wang, Yuehua, Chen, Qichen, Yang, Minjie, Guo, Xi, Tong, Zhou, Qi, Zhirong, Zhao, Fuxing, Yan, Xiaofei, Zhao, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520203/
https://www.ncbi.nlm.nih.gov/pubmed/36188432
http://dx.doi.org/10.1016/j.eclinm.2022.101667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520203/
https://www.ncbi.nlm.nih.gov/pubmed/36188432
http://dx.doi.org/10.1016/j.eclinm.2022.101667

Ejemplares similares